Acute optic neuritis: Unmet clinical needs and model for new therapies

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 4, 2015, Pages

  Galetta, Steven L ^a   Villoslada, Pablo ^b,c   Levin, Netta ^d   Shindler, Kenneth ^e   Ishikawa, Hiroshi ^f,g   Parr, Edward ^h   Cadavid, Diego ⁱ   Balcer, Laura J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f University of Pittsburgh School of Medicine   (United States)

^g PA 15260   (United States)

^h Excel Scientific Solutions   (United States)

ⁱ BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IMMUNOGLOBULIN; MEPREDNISONE; OPICINUMAB; SIMVASTATIN;

ARTICLE; DISEASE COURSE; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; VISION; VISUAL ACUITY; VISUAL EVOKED POTENTIAL;

EID: 84994431739     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000135     Document Type: Article

References (60)

1. Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol 2014; 13: 83-99.
2. Beck RW, Cleary PA, Anderson MM Jr, et al. Optic Neuritis Study Group. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326: 581-588.
3. Cole SR, Beck RW, Moke PS, Gal RL. Long DT; Optic Neuritis Study Group. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Invest Ophthalmol Vis Sci 2000; 41: 1017-1021.
4. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994; 101: 1771-1778.
5. Costello F, Hodge W, Pan YI, Eggenberger E, Coupland S, Kardon RH. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mult Scler 2008; 14: 893-905.
6. Brusa A, Jones SJ, Plant GT. Long-term remyelination after optic neuritis: a 2-year visual evoked potential and psychophysical serial study. Brain 2001; 124: 468-479.
7. Malik MT, Healy BC, Benson LA, et al. Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology 2014; 82: 2173-2179.
8. Raz N, Dotan S, Chokron S, Ben-Hur T, Levin N. Demyelination affects temporal aspects of perception: an optic neuritis study. Ann Neurol 2012; 71: 531-538.
9. Leat SJ, Legge GE, Bullimore MA. What is low vision? A reevaluation of definitions. Optom Vis Sci 1999; 76: 198-211.
10. Martínez-Lapiscina EH, Ortiz-Pérez S, Fraga-Pumar E, et al. Colour vision impairment is associated with disease severity in multiple sclerosis. Mult Scler 2014; 20: 1207-1216.
11. Raz N, Dotan S, Benoliel T, Chokron S, Ben-Hur T, Levin N. Sustained motion perception deficit following optic neuritis: behavioral and cortical evidence. Neurology 2011; 76: 2103-2111.
12. Pineles SL, Birch EE, Talman LS, et al. One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol 2011; 152: 133-140.
13. Gabriele ML, Wollstein G, Ishikawa H, et al. Optical coherence tomography: history, current status, and laboratory work. Invest Ophthalmol Vis Sci 2011; 52: 2425-2436.
14. Henderson AP, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010; 133: 2592-2602.
15. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010; 9: 921-932.
16. Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, et al. Dynamics of retinal injury after acute optic neuritis. Ann Neurol 2015; 77: 517-528.
17. Huang-Link Y-M, Al-Hawasi A. Lindehammar H. Acute optic neuritis: retinal ganglion cell loss precedes retinal nerve fiber thinning. Neurol Sci 2015; 36: 617-620.
18. Trip SA, Schlottmann PG, Jones SJ, et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005; 58: 383-391.
19. Henderson AP, Altmann DR, Trip SA, et al. Early factors associated with axonal loss after optic neuritis. Ann Neurol 2011; 70: 955-963.
20. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59: 963-969.
21. Hood DC, Anderson SC, Wall M, Kardon RH. Structure versus function in glaucoma: an application of a linear model. Invest Ophthalmol Vis Sci 2007; 48: 3662-3668.
22. Balk LJ, Steenwijk MD, Tewarie P, et al. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 86: 419-424.
23. Gabilondo I, Martínez-Lapiscina EH, Martínez-Heras E, et al. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol 2014; 75: 98-107.
24. Alshowaeir D, Yiannikas C, Garrick R, et al. Latency of multifocal visual evoked potentials in nonoptic neuritis eyes of multiple sclerosis patients associated with optic radiation lesions. Invest Ophthalmol Vis Sci 2014; 55: 3758-3764.
25. Sakai RE, Feller DJ, Galetta KM, Galetta SL, Balcer LJ. Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol 2011; 31: 362-373.
26. Walter SD, Ishikawa H, Galetta KM, et al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology 2012; 119: 1250-1257.
27. Di Maggio G, Santangelo R, Guerrieri S, et al. Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis? Mult Scler 2014; 20: 1342-1347.
28. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology 2009; 73: 46-52.
29. Araie M. Test-retest variability in structural parameters measured with glaucoma imaging devices. Jpn J Ophthalmol 2013; 57: 1-24.
30. Watson GM, Keltner JL, Chin EK, Harvey D, Nguyen A, Park SS. Comparison of retinal nerve fiber layer and central macular thickness measurements among five different optical coherence tomography instruments in patients with multiple sclerosis and optic neuritis. J Neuroophthalmol 2011; 31: 110-116.
31. Schippling S, Balk L, Costello F, et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler 2015; 21: 163-170.
32. Rinalduzzi S, Brusa A, Jones SJ. Variation of visual evoked potential delay to stimulation of central, nasal, and temporal regions of the macula in optic neuritis. J Neurol Neurosurg Psychiatry 2001; 70: 28-35.
33. Hood DC, Odel JG, Winn BJ. The multifocal visual evoked potential. J Neuroophthalmol 2003; 23: 279-289.
34. Jenkins T, Ciccarelli O, Toosy A, et al. Dissecting structurefunction interactions in acute optic neuritis to investigate neuroplasticity. Hum Brain Mapp 2010; 31: 276-286.
35. Klistorner A, Arvind H, Garrick R, Graham SL, Paine M, Yiannikas C. Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. Invest Ophthalmol Vis Sci 2010; 51: 2770-2777.
36. Klistorner A, Arvind H, Nguyen T, et al. Axonal loss and myelin in early ON loss in postacute optic neuritis. Ann Neurol 2008; 64: 325-331.
37. Klistorner A, Arvind H, Nguyen T, et al. Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol 2009; 118: 129-137.
38. Yang EB, Hood DC, Rodarte C, Zhang X, Odel JG, Behrens MM. Improvement in conduction velocity after optic neuritis measured with the multifocal VEP. Invest Ophthalmol Vis Sci 2007; 48: 692-698.
39. Cadavid D, Levin N, Costello F, Rahilly A, Klistorner A. Technical feasibility of implementing multifocal VEP for multicenter clinical trials. Neurology 2013; 80: P02.245.
40. Grossman RI Magnetization transfer in multiple sclerosis. Ann Neurol 1994; 36(suppl): S97-S99.
41. Le Bihan D, Mangin JF, Poupon C, et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001; 13: 534-546.
42. Melzi L, Rocca MA, Marzoli SB, et al. A longitudinal conventional and magnetization transfer magnetic resonance imaging study of optic neuritis. Mult Scler 2007; 13: 265-268.
43. Wang Y, van der Walt A, Paine M, et al. Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes. PLoS One 2012; 7: e52291.
44. Naismith RT, Xu J, Tutlam NT, et al. Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology 2009; 72: 589-594.
45. Naismith RT, Xu J, Tutlam NT, et al. Diffusion tensor imaging in acute optic neuropathies: predictor of clinical outcomes. Arch Neurol 2012; 69: 65-71.
46. Xu J, Sun SW, Naismith RT, Snyder AZ, Cross AH, Song SK. Assessing optic nerve pathology with diffusion MRI: from mouse to human. NMR Biomed 2008; 21: 928-940.
47. Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 2008; 14: 988-991.
48. Schinzel J, Zimmermann H, Paul F, et al. Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. BMC Neurol 2014; 14: 31.
49. Mowry EM, Loguidice MJ, Daniels AB, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry 2009; 80: 767-772.
50. Raz N, Hallak M, Ben-Hur T, Levin N. Dynamic visual tests to identify and quantify visual damage and repair following demyelination in optic neuritis patients. J Vis Exp Epub 2014 Apr 14. doi: 10.3791/51107.
51. Raphael BA, Galetta KM, Jacobs DA, et al. Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol 2006; 142: 1026-1035.
52. Nolan RC, Galetta KM, Wilson JA, et al. Quality of life after optic neuritis in MS: new data for the 10-item neuroophthalmic supplement to the NEI-VFQ-25. Poster presented at: 40th Annual Meeting of the North American Neuro-Ophthalmology Society; March 1-6, 2014; Rio Grande, Puerto Rico.
53. Sühs KW, Hein K, Pehlke JR. Käsmann-Kellner B, Diem R. Retinal nerve fibre layer thinning in patients with clinically isolated optic neuritis and early treatment with interferon-beta. PLoS One 2012; 7: e51645.
54. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007; 68: 1299-1304.
55. Meuth SG, Bittner S, Seiler C, Gobel K, Wiendl H. Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis. Mult Scler 2011; 17: 198-203.
56. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-1522.
57. Sühs KW, Hein K, Sättler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012; 72: 199-210.
58. Tsakiri A, Kallenbach K, Fuglø D, Wanscher B, Larsson H. Frederiksen J. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 2012; 18: 72-81.
59. Johnson MA, Cadavid D. Simvastatin in acute optic neuritis. Mult Scler 2012; 18: 1657; author reply 1658.
60. Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm 2014; 1: e18. doi: 10.1212/NXI.0000000000000018.